Results 31 to 40 of about 6,454 (219)

Eficacia comparativa de Tirzepatida, Teneligliptina y Empagliflozina en la reducción de la HbA1c en pacientes con Diabetes tipo 2: Una revisión sistemática y meta-análisise [PDF]

, 2023
This study’s objective was to evaluate the effectiveness of three different families of drugs (Empagliflozin [an SGLT-2 inhibitor], Tirzepatide [a GLP-1 receptor co-agonist], and Teneligliptin [DPP-4 inhibitor] used in the treatment of type 2 diabetes in
Benitez-Acosta, Karen, Delgado-Quijano, Fabian, Fernandez-Arcos, Anthony, Hurtado-Alzate, Claudia, Llerena-Velastegui, Jordan, Santafe-Abril, Gerson, Trujillo-Delgado, Martin, Villacis-Lopez, Cecibel   +7 more
core   +2 more sources

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, EarlyView.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Cardiovascular Diabetology, 2022
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin ...
Michael A. Nauck, David A. D‘Alessio
doaj   +1 more source

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Purpose: A systematic review and meta-analysis was conducted to combine the data available from clinical trials and evaluate the clinical efficacy and safety of tirzepatide in people with type 2 diabetes (T2D).Methods: We systematically searched the ...
Yan Tang, Lin Zhang, Yuping Zeng, Xia Wang, Mei Zhang   +4 more
doaj   +1 more source

Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics

Lipids in Health and Disease
Clinical studies have suggested that tirzepatide may also possess hepatoprotective effects; however, the molecular mechanisms underlying this association remain unclear.
Jinliang Liang, Huanyi Liu, Guo Lv, Xiaotong Chen, Zhaoshou Yang, Kunhua Hu, Hongyan Sun   +6 more
doaj   +1 more source

Evidence that tirzepatide protects against diabetes-related cardiac damages [PDF]

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE), their impact
Barbieri, Michelangela, Fontanella, Rosaria Anna, Franzese, Martina, Ghosh, Puja, Olivieri, Fabiola, Paolisso, Giuseppe, Pesapane, Ada, Puocci, Armando, Scisciola, Lucia, Signoriello, Giuseppe, Sommella, Eduardo, Taktaz, Fatemeh, Tortorella, Giovanni   +12 more
core   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Tirzepatide: A Systematic Update

International Journal of Molecular Sciences, 2022
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity ...
Forzano, Imma, Varzideh, Fahimeh, Avvisato, Roberta, Jankauskas, Stanislovas S, Mone, Pasquale, Santulli, Gaetano   +5 more
openaire   +2 more sources

A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use

Endocrinology, Diabetes & Metabolism Case Reports
Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia ...
Basil Nduma, Sai Nikhitha Malapati, Veeranna Vibhuti   +2 more
doaj   +1 more source

Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes

The Laryngoscope, EarlyView.
ABSTRACT Objective The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population.
Praneet C. Kaki, Troy Wesson, Alison Choi, Sophia Shah, Thomas Kaffenberger, Ryan Soose, Noah Parker, Maurits Boon, Colin Huntley, Chihun Jim Han   +9 more
wiley   +1 more source